Viewing Study NCT02694718


Ignite Creation Date: 2025-12-25 @ 4:36 AM
Ignite Modification Date: 2026-01-10 @ 1:46 AM
Study NCT ID: NCT02694718
Status: COMPLETED
Last Update Posted: 2017-01-11
First Post: 2016-02-25
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer
Sponsor: Hoffmann-La Roche
Organization:

Study Overview

Official Title: A Phase II Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer
Status: COMPLETED
Status Verified Date: 2016-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine the pathological complete tumor response rate.
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: